30 October 2026
Novartis is betting big on a new MS pill. Not everyone is convinced it works well enough
Novartis says remibrutinib could make more than $4 billion a year in multiple sclerosis, but trial results showed fewer prevented relapses than analysts hoped.
Every big drugmaker lives with a countdown clock: once a bestseller's patents expire, cheaper copies arrive and sales fall away. Novartis is leaning on an experimental multiple sclerosis (MS) pill called remibrutinib to help fill the next gap. Its CEO is enthusiastic. Some analysts and doctors are more cautious.
What happened
Novartis says remibrutinib can reach more than $4 billion in peak annual sales (its best yearly sales once fully launched) in relapsing MS, the form where patients have flare-ups. Across all its possible uses, the company is guiding for more than $8 billion. CEO Vas Narasimhan told CNBC it "could be one of our largest medicines in history."
Days earlier, Barclays cut its own sales forecast after full results from two late-stage trials showed the drug reduced relapses by less than analysts expected. A University of Pennsylvania MS specialist told CNBC the drug looks safe but probably controls relapses less well than antibody drugs such as Novartis' own Kesimpta. No trial has yet compared them head to head.
The two work differently. Remibrutinib is a BTK inhibitor, which calms the immune cells that damage nerves in MS. Kesimpta removes some of those cells entirely. The Penn specialist said that gentler approach could prove safer over many years, but there is not yet enough long-term data to show it.
Why it matters
Barclays says investors' bigger question is the next patent cliff: Kisqali, a breast cancer drug, and Kesimpta both lose patent protection around 2032, and together they represent $18 billion in peak sales. For scale, Novartis earned about $14 billion of net income in 2025, according to its filings, and has a stock market value of roughly $298 billion.
Novartis says remibrutinib is meant to add to Kesimpta, not replace it. It is targeting newly diagnosed patients, people on older pills who want to switch, and patients on anti-CD20 antibody drugs who may be eligible to switch, including those on Ocrevus from Roche, which leads the market. A Morningstar analyst called the $4 billion goal possible but not yet proven.
There is a second front too. Remibrutinib is already approved for some forms of chronic hives, and is being tested in hidradenitis suppurativa, a painful skin disease. Barclays sees a $2 billion opportunity there but gives the trial only even odds of success.
What to watch
- The skin disease trial result, due before November 19.
- Novartis' long-term growth plan, due in mid-November.
- The RESHAPE trial in patients switching from Ocrevus, due in 2028.
Novartis' financials are on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Novartis remibrutinib MS drug faces efficacy questions. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion